Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

3.620 -0.040 (-1.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 37,955
Open 3.780
Bid (Size) 3.510 (500)
Ask (Size) 3.750 (200)
Prev. Close 3.660
Today's Range 3.555 - 3.780
52wk Range 1.300 - 4.750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
From Adagene Inc.
Via GlobeNewswire

Performance

YTD
+96.7%
+96.7%
1 Month
-9.3%
-9.3%
3 Month
+23.1%
+23.1%
6 Month
+102.2%
+102.2%
1 Year
+136.6%
+136.6%

More News

Read More
News headline image
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
From Adagene Inc.
Via GlobeNewswire
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic ↗
Via Stocktwits
News headline image
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
From Adagene Inc.
Via GlobeNewswire
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
Adagene to Participate in Two Upcoming Investor Conferences
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Provides Business Update and 2026 Objectives
From Adagene Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
From Adagene Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
From Adagene Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene to Participate in Two Investor Conferences in September
From Adagene Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
From Adagene Inc.
Via GlobeNewswire
News headline image
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
Via Benzinga
News headline image
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
From Adagene Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Adagene Inc. - ADS, each representing 1.25 ordinary shares publicly traded?
Yes, Adagene Inc. - ADS, each representing 1.25 ordinary shares is publicly traded.
What exchange does Adagene Inc. - ADS, each representing 1.25 ordinary shares trade on?
Adagene Inc. - ADS, each representing 1.25 ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares?
The ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares is ADAG on the Nasdaq Stock Market
What is the current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares?
The current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares is 3.620
When was Adagene Inc. - ADS, each representing 1.25 ordinary shares last traded?
The last trade of Adagene Inc. - ADS, each representing 1.25 ordinary shares was at 05/05/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.